Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year High - Still a Buy?

Key Points

• 52-week high: Amicus shares reached a new 52-week high of $14.43, with a market cap of about $4.53 billion and the 50-day/200-day moving averages at $14.34 and $11.66 respectively, indicating recent upward momentum.
• Analyst consensus — Hold: The consensus rating is "Hold" with a $15.39 price target (3 Buys, 9 Holds, 1 Sell) and several recent downgrades and lowered targets from firms like Jefferies, Guggenheim and Citigroup.
• Earnings mixed: Q4 EPS missed at $0.10 versus $0.13 expected, but revenue rose 23.7% year-over-year to $185.21 million; meanwhile CEO Bradley Campbell sold 75,000 shares, reducing his stake by about 6.8%.

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s share price hit a new 52-week high during trading on Monday . The company traded as high as $14.43 and last traded at $14.4250, with a volume of 35649 shares. The stock had previously closed at $14.43.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on FOLD shares. Jefferies Financial Group reiterated a "hold" rating and issued a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Amicus Therapeutics in a report on Friday. Guggenheim downgraded shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 5th. Needham & Company LLC lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 19th. Finally, Citigroup reissued a "neutral" rating and set a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $15.39.

Amicus Therapeutics Price Performance

The stock has a market cap of $4.53 billion, a price-to-earnings ratio of -180.31 and a beta of 0.43. The company has a 50 day simple moving average of $14.34 and a 200-day simple moving average of $11.66. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. During the same period in the prior year, the business posted $0.09 EPS. The firm's quarterly revenue was up 23.7% compared to the same quarter last year. Research analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total value of $1,073,250.00. Following the transaction, the chief executive officer owned 1,021,180 shares in the company, valued at $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Signaturefd LLC lifted its stake in Amicus Therapeutics by 32.7% in the 4th quarter. Signaturefd LLC now owns 2,895 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 714 shares during the last quarter. Gotham Asset Management LLC grew its stake in Amicus Therapeutics by 0.7% during the fourth quarter. Gotham Asset Management LLC now owns 139,551 shares of the biopharmaceutical company's stock worth $1,987,000 after purchasing an additional 1,028 shares during the period. GAMMA Investing LLC increased its holdings in Amicus Therapeutics by 167.1% in the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,243 shares in the last quarter. Allworth Financial LP increased its holdings in Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,246 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its stake in Amicus Therapeutics by 0.3% in the third quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company's stock valued at $3,066,000 after buying an additional 1,333 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.